Early stage

Ergomed is developing first-in-class clotting agents for the treatment of bleeding or 'haemostasis'.  The Company has pioneered a new approach to the control of bleeding that is based on a peptide that binds to the clotting protein fibrinogen, inducing the rapid and targeted formation of clots. This innovative technology platform is being used to develop a pipeline of topical and systemic products to prevent or control different forms of bleeding, including its first product, PeproStat™.

PeproStat™ is targeted at a very large global market with clear unmet needs.  It has clear potential advantages over other products in the market, including the ability to more quickly stop bleeding in surgical patients.

Our original investment was in Leicester University spin-out company, Haemostatix Limited, and we supported the research and development of the company's products and assisted it to assemble a highly experienced management team. In May 2016, Haemostatix was sold to Ergomed plc and we are now a shareholder in that business which is listed on AIM.

Our Approach

What do we look for?

Our business is about forming long term relationships with exceptional entrepreneurs and becoming a trusted partner and supportive investor.

We look for companies with both the vision and potential to become ‘game changers’ and market leaders across a range of sectors.

learn more

Our Team

Rob Carroll

view complete team

Contact us

Binder House
7 Narborough Wood Park
Desford Road
LE19 4XT

Tel: 0116 238 8200